Frida Carvajal‐Medina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Frida Carvajal‐Medina has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abril Verónica Mendoza‐Vigueras
Department of Immunology and Rheumatology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City (CDMX) Mexico
1 shared publication - Guillermo Arturo Guaracha-Basañez
Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
1 shared publication Irazú Contreras‐Yáñez
Department of Immunology and Rheumatology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City (CDMX) Mexico
1 shared publicationJulia Giselle Jiménez‐Decle
Department of Immunology and Rheumatology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City (CDMX) Mexico
1 shared publicationLaura Viviana Vargas‐Sánchez
Department of Immunology and Rheumatology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City (CDMX) Mexico
1 shared publication- Mariana Lourdes López‐Ávila
Department of Immunology and Rheumatology Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán Mexico City (CDMX) Mexico
1 shared publication
Latest Publications
- 3 November 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (8)
Higher Daily Hospitalization Costs and Intensive Care Utilization Among Decedents With Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Bioethical Analysis of End‐of‐Life Care
Introduction: End‐of‐life care creates financial burdens. This study examines medical procedures/interventions and costs for inpatients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), comparing those who died during hospitalization to those who survived, analyzing the findings through a bioethical perspective. Methods: This observational 1:1 case‐control study was conducted at a tertiary care center. Patients with SLE and RA (ICD‐10‐CM diagnostic codes) who were hospitalized for at least 24 h during two distinct periods—January–June 2019 and January–June 2023—were included. Patients were designated as cases if they died during hospitalization and as controls if they were discharged alive. Data were abstracted from electronic medical records using standardized formats. Microcosting data for each hospitalization were obtained from the accounting department. Results: We identified 29 matched pairs of cases and controls, primarily comprising middle‐aged females, with SLE. Cases and controls had similar sociodemographic and disease‐related characteristics. However, cases spent a greater proportion of their hospitalization time in the intensive care unit (100% [33.9–100] vs. 27.5% [13.4–45], p ≤ 0.001) and had higher incidence of complications (75.9% vs. 34.5%, p = 0.003). Daily hospitalization costs were significantly higher for cases (USD 3348 vs. 2707.4, p = < 0.001). More cases utilized blood bank services, while fewer engaged in clinical nutrition‐related procedures. Conclusions: Decedents with SLE/RA had higher daily hospitalization costs than matched survivors, in the context of greater ICU utilization, complications, and blood bank use. End‐of‐life scenarios are complex; clinical decisions should be examined through bioethical lens.
- 3 November 2026
- Published by Wiley in Journal of Evaluation in Clinical Practice
- Vol. 32 (8)
Higher Daily Hospitalization Costs and Intensive Care Utilization Among Decedents With Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Bioethical Analysis of End‐of‐Life Care
Introduction: End‐of‐life care creates financial burdens. This study examines medical procedures/interventions and costs for inpatients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), comparing those who died during hospitalization to those who survived, analyzing the findings through a bioethical perspective. Methods: This observational 1:1 case‐control study was conducted at a tertiary care center. Patients with SLE and RA (ICD‐10‐CM diagnostic codes) who were hospitalized for at least 24 h during two distinct periods—January–June 2019 and January–June 2023—were included. Patients were designated as cases if they died during hospitalization and as controls if they were discharged alive. Data were abstracted from electronic medical records using standardized formats. Microcosting data for each hospitalization were obtained from the accounting department. Results: We identified 29 matched pairs of cases and controls, primarily comprising middle‐aged females, with SLE. Cases and controls had similar sociodemographic and disease‐related characteristics. However, cases spent a greater proportion of their hospitalization time in the intensive care unit (100% [33.9–100] vs. 27.5% [13.4–45], p ≤ 0.001) and had higher incidence of complications (75.9% vs. 34.5%, p = 0.003). Daily hospitalization costs were significantly higher for cases (USD 3348 vs. 2707.4, p = < 0.001). More cases utilized blood bank services, while fewer engaged in clinical nutrition‐related procedures. Conclusions: Decedents with SLE/RA had higher daily hospitalization costs than matched survivors, in the context of greater ICU utilization, complications, and blood bank use. End‐of‐life scenarios are complex; clinical decisions should be examined through bioethical lens.